BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 10550825)

  • 1. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
    Chen AY; Chou R; Shih SJ; Lau D; Gandara D
    Crit Rev Oncol Hematol; 2004 May; 50(2):111-9. PubMed ID: 15157660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
    Chen AY; Okunieff P; Pommier Y; Mitchell JB
    Cancer Res; 1997 Apr; 57(8):1529-36. PubMed ID: 9108456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan and radiation in combined-modality therapy for solid tumors.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):22-8. PubMed ID: 11497228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
    Cho LC; Choy H
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):29-39. PubMed ID: 15255165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
    Zhao M; Gjerset RA
    PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA topoisomerase I inhibitors.
    Takimoto CH; Kieffer LV; Arbuck SG
    Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
    [No Abstract]   [Full Text] [Related]  

  • 10. DNA topoisomerase I poisons.
    Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
    Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
    [No Abstract]   [Full Text] [Related]  

  • 11. [Topoisomerase I inhibitor with potential radiosensitizing effect].
    Sauer R; Heuser A
    Strahlenther Onkol; 1997 Mar; 173(3):125-30. PubMed ID: 9122851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials using irinotecan.
    Houghton PJ; Santana VM
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
    Pantazis P
    Clin Cancer Res; 1995 Nov; 1(11):1235-44. PubMed ID: 9815917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
    Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
    Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
    van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
    J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R; al-Said NH; Sternbach DL; Lown JW
    J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of ionizing radiation with topotecan in two human tumor cell lines.
    Marchesini R; Colombo A; Caserini C; Perego P; Supino R; Capranico G; Tronconi M; Zunino F
    Int J Cancer; 1996 May; 66(3):342-6. PubMed ID: 8621255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.